Featured Research

from universities, journals, and other organizations

Vaccine Against HER2-positive Breast Cancer Offers Complete Protection In Lab

Date:
September 15, 2008
Source:
American Association for Cancer Research
Summary:
Researchers have tested a breast cancer vaccine they say completely eliminated HER2-positive tumors in mice -- even cancers resistant to current anti-HER2 therapy --- without any toxicity.

Researchers at Wayne State University have tested a breast cancer vaccine they say completely eliminated HER2-positive tumors in mice - even cancers resistant to current anti-HER2 therapy - without any toxicity.

The study, reported in the September 15 issue of Cancer Research, a journal of the American Association for Cancer Research, suggests the vaccine could treat women with HER2-positive, treatment-resistant cancer or help prevent cancer recurrence. The researchers also say it might potentially be used in cancer-free women to prevent initial development of these tumors.

HER2 receptors promote normal cell growth, and are found in low amounts on normal breast cells. But HER2-positive breast cells can contain many more receptors than is typical, promoting a particularly aggressive type of tumor that affects 20 to 30 percent of all breast cancer patients. Therapies such as trastuzumab and lapatinib, designed to latch on to these receptors and destroy them, are a mainstay of treatment for this cancer, but a significant proportion of patients develop a resistance to them or cancer metastasis that is hard to treat.

This treatment relied on activated, own-immunity to wipe out the cancer, says the study's lead investigator, Wei-Zen Wei, Ph.D., a professor of immunology and microbiology at the Karmanos Cancer Institute.

"The immune response against HER2-positive receptors we saw in this study is powerful, and works even in tumors that are resistant to current therapies," she said. "The vaccine could potentially eliminate the need to even use these therapies."

The vaccine consists of "naked" DNA – genes that produce the HER2 receptor – as well as an immune stimulant. Both are housed within an inert bacterial plasmid. In this study, the researchers used pulses of electricity to deliver the injected vaccine into leg muscles in mice, where the gene produced a huge quantity of HER2 receptors that activated both antibodies and killer T cells.

"While HER2 receptors are not usually seen by the immune system when they are expressed at low level on the surface of normal cells, a sudden flood of receptors alerts the body to an invasion that needs to be eliminated," Wei said. "During that process, the immune system learns to attack cancer cells that display large numbers of these receptors."

They also used an agent that, for a while, suppressed the activity of regulatory T cells, which normally keeps the immune system from over-reacting. In the absence of regulatory T cells, the immune system responded much more strongly to the vaccine. Then, when the researchers implanted HER2-positive breast tumors in the animals, the cancer was eradicated.

"Both tumor cells that respond to current targeted therapies and those that are resistant to these treatments were eradicated," Wei said. "This may be an answer for women with these tumors who become resistant to the current therapies."

Wei's lab is the first to develop HER2 DNA vaccines, and this is the second such vaccine Wei and her colleagues have tested more extensively. The first, described in a study in 1999, formed the model of a vaccine now being tested by a major Pharmaceutical company in early phase clinical trials in the U.S. and in Europe in women with HER2-positive breast cancer.

In order to ensure complete safety, Wei says the current test vaccine uses HER2 genes that are altered so that they cannot be oncogenic. The receptors produced do not contain an "intracellular domain" – the part of the receptor that is located just below the cell surface and transmits growth signals to the nucleus. The first vaccine was also safe, she says, but contained a little more of the native HER2 receptor structure. "With this vaccine, I am quite certain the receptor is functionally dead," she said.

"The greatest power of vaccination is protection against initial cancer development, and that is our ultimate goal with this treatment," Wei said.


Story Source:

The above story is based on materials provided by American Association for Cancer Research. Note: Materials may be edited for content and length.


Cite This Page:

American Association for Cancer Research. "Vaccine Against HER2-positive Breast Cancer Offers Complete Protection In Lab." ScienceDaily. ScienceDaily, 15 September 2008. <www.sciencedaily.com/releases/2008/09/080915083343.htm>.
American Association for Cancer Research. (2008, September 15). Vaccine Against HER2-positive Breast Cancer Offers Complete Protection In Lab. ScienceDaily. Retrieved July 24, 2014 from www.sciencedaily.com/releases/2008/09/080915083343.htm
American Association for Cancer Research. "Vaccine Against HER2-positive Breast Cancer Offers Complete Protection In Lab." ScienceDaily. www.sciencedaily.com/releases/2008/09/080915083343.htm (accessed July 24, 2014).

Share This




More Health & Medicine News

Thursday, July 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
Can Watching TV Make You Feel Like A Failure?

Can Watching TV Make You Feel Like A Failure?

Newsy (July 24, 2014) A study by German researchers claims watching TV while you're stressed out can make you feel guilty and like a failure. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile: iPhone Android Web
          Follow: Facebook Twitter Google+
          Subscribe: RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins